Abbvie Inc. Common Stock (ABBV) 63.63 $ABBV
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 63.63 (-0.13)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.42 (unch), ABBV: 63.63 (-0.13)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.49 (-1.36), MRK: 59.54 (+0.23), ABBV: 63.63 (-0.13)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.21 (-0.30), JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ABBV: 63.63 (-0.13)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 104.20 (-2.70), ABBV: 63.63 (-0.13)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.21 (-0.30), ABBV: 63.63 (-0.13), SNY: 46.53 (-0.03), REGN: 402.63 (+1.52)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.72 (-3.96), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), DNDN: 0.13 (-0.03), AMGN: 160.85 (-1.08), ABBV: 63.63 (-0.13), REGN: 402.63 (+1.52)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.71 (+1.41), ACT: 241.63 (+1.01), CBG: 32.69 (-0.02), HCP: 43.92 (+0.62), BCR: 165.59 (+0.38), PCG: 49.77 (-0.37), AMGN: 160.85 (-1.08), CB: 101.47 (-0.05), SRE: 109.51 (-1.14), PLD: 41.10 (+0.10), HSP: 58.09 (unch), TWX: 78.98 (+1.30), KIM: 24.74 (+0.14), CMI: 144.52 (-1.97), ALXN: 193.59 (-0.10), ESS: 200.52 (+0.08), ABBV: 63.63 (-0.13), CAT: 101.11 (-1.88), AAPL: 112.82 (+1.57)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.21 (-0.30), GILD: 104.20 (-2.70), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 63.63 (-0.13)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 202.42 (+1.91), PFE: 30.42 (unch), AZN: 74.53 (+0.27), ABBV: 63.63 (-0.13), WAG: 66.96 (-0.48)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), MRK: 59.54 (+0.23), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), MRK: 59.54 (+0.23), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 112.72 (-3.96), GILD: 104.20 (-2.70), MRK: 59.54 (+0.23), DNDN: 0.13 (-0.03), AZN: 74.53 (+0.27), TEVA: 57.17 (-1.27), ABBV: 63.63 (-0.13), GSK: 45.66 (+0.04), BMY: 57.80 (-0.81), NVS: 94.38 (+1.72)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 379.41 (-4.45), YHOO: 50.50 (-0.10), AMZN: 316.48 (+4.97), BIIB: 317.98 (-3.04), VRTX: 112.72 (-3.96), FEYE: 33.34 (+0.19), LNKD: 229.77 (-1.36), EBAY: 54.37 (+0.31), GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), ABBV: 63.63 (-0.13), REGN: 402.63 (+1.52), CELG: 107.43 (-0.82)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), MRK: 59.54 (+0.23), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), MRK: 59.54 (+0.23), LGND: 57.96 (+0.26), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), LGND: 57.96 (+0.26), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 8:00AM CST
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.63 (-0.13), ENTA: 43.22 (-0.09)
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 7:00AM CST
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.63 (-0.13), ENTA: 43.22 (-0.09)
AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)
PR Newswire - Thu Nov 13, 8:00AM CST
AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational medicines will be presented at the upcoming 2014 American College of Rheumatology (ACR) Annual Meeting, November 14 - 19, in Boston. As a long-standing expert in the field of rheumatology with its experience with HUMIRA, AbbVie continues to build on its leadership with data focused on investigational medicines to create innovative solutions for rheumatologic diseases.
ABBV: 63.63 (-0.13)
Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.42 (unch), ABBV: 63.63 (-0.13)
Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 13.49 (-1.36), MRK: 59.54 (+0.23), ABBV: 63.63 (-0.13)
Gilead Reports Promising Data on its HCV Drug Harvoni - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:00PM CST
Gilead Sciences, Inc. (GILD) announced pooled data from certain phase II and phase III studies evaluating Harvoni.
AGN: 196.21 (-0.30), JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ABBV: 63.63 (-0.13)
Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie
Small Pharma Analyst - at Seeking Alpha - Wed Nov 12, 2:25PM CST
GILD: 104.20 (-2.70), ABBV: 63.63 (-0.13)
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 10:00AM CST
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.21 (-0.30), ABBV: 63.63 (-0.13), SNY: 46.53 (-0.03), REGN: 402.63 (+1.52)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 112.72 (-3.96), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), DNDN: 0.13 (-0.03), AMGN: 160.85 (-1.08), ABBV: 63.63 (-0.13), REGN: 402.63 (+1.52)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 142.71 (+1.41), ACT: 241.63 (+1.01), CBG: 32.69 (-0.02), HCP: 43.92 (+0.62), BCR: 165.59 (+0.38), PCG: 49.77 (-0.37), AMGN: 160.85 (-1.08), CB: 101.47 (-0.05), SRE: 109.51 (-1.14), PLD: 41.10 (+0.10), HSP: 58.09 (unch), TWX: 78.98 (+1.30), KIM: 24.74 (+0.14), CMI: 144.52 (-1.97), ALXN: 193.59 (-0.10), ESS: 200.52 (+0.08), ABBV: 63.63 (-0.13), CAT: 101.11 (-1.88), AAPL: 112.82 (+1.57)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.21 (-0.30), GILD: 104.20 (-2.70), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 63.63 (-0.13)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 202.42 (+1.91), PFE: 30.42 (unch), AZN: 74.53 (+0.27), ABBV: 63.63 (-0.13), WAG: 66.96 (-0.48)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), MRK: 59.54 (+0.23), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), MRK: 59.54 (+0.23), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 112.72 (-3.96), GILD: 104.20 (-2.70), MRK: 59.54 (+0.23), DNDN: 0.13 (-0.03), AZN: 74.53 (+0.27), TEVA: 57.17 (-1.27), ABBV: 63.63 (-0.13), GSK: 45.66 (+0.04), BMY: 57.80 (-0.81), NVS: 94.38 (+1.72)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 379.41 (-4.45), YHOO: 50.50 (-0.10), AMZN: 316.48 (+4.97), BIIB: 317.98 (-3.04), VRTX: 112.72 (-3.96), FEYE: 33.34 (+0.19), LNKD: 229.77 (-1.36), EBAY: 54.37 (+0.31), GILD: 104.20 (-2.70), AMGN: 160.85 (-1.08), ABBV: 63.63 (-0.13), REGN: 402.63 (+1.52), CELG: 107.43 (-0.82)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), MRK: 59.54 (+0.23), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), MRK: 59.54 (+0.23), LGND: 57.96 (+0.26), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 109.07 (+0.32), GILD: 104.20 (-2.70), ACHN: 13.49 (-1.36), CNAT: 7.15 (+0.25), LGND: 57.96 (+0.26), RGLS: 17.74 (-1.88), ABBV: 63.63 (-0.13), BMY: 57.80 (-0.81), ENTA: 43.22 (-0.09)
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 8:00AM CST
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.63 (-0.13), ENTA: 43.22 (-0.09)
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 7:00AM CST
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.63 (-0.13), ENTA: 43.22 (-0.09)
